These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16596210)

  • 1. Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours.
    Santini D; Vincenzi B; Hannon RA; Brown JE; Dicuonzo G; Angeletti S; La Cesa A; Coleman RE; Tonini G; Budillon A; Caraglia M; Holen I
    Oncol Rep; 2006 May; 15(5):1351-7. PubMed ID: 16596210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.
    Santini D; Vincenzi B; Dicuonzo G; Avvisati G; Massacesi C; Battistoni F; Gavasci M; Rocci L; Tirindelli MC; Altomare V; Tocchini M; Bonsignori M; Tonini G
    Clin Cancer Res; 2003 Aug; 9(8):2893-7. PubMed ID: 12912933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone: the effect of zoledronic acid.
    Polyzos SA; Anastasilakis AD; Efstathiadou Z; Litsas I; Kita M; Panagiotou A; Papatheodorou A; Arsos G; Moralidis E; Barmpalios G; Zafeiriadou E; Triantafillidou E; Makrigiannaki E; Terpos E
    J Bone Miner Metab; 2010 May; 28(3):314-9. PubMed ID: 19841860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.
    Francini F; Pascucci A; Bargagli G; Francini E; Conca R; Miano ST; Martellucci I; Migali C; Gotti G; Fiaschi AI; Cozzolino A; Petrioli R
    Int J Clin Oncol; 2011 Jun; 16(3):264-9. PubMed ID: 21240683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.
    Lipton A; Cook R; Brown J; Body JJ; Smith M; Coleman R
    Clin Oncol (R Coll Radiol); 2013 Apr; 25(4):217-26. PubMed ID: 23219232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients.
    Santini D; Vincenzi B; Galluzzo S; Battistoni F; Rocci L; Venditti O; Schiavon G; Angeletti S; Uzzalli F; Caraglia M; Dicuonzo G; Tonini G
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4482-6. PubMed ID: 17671133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.
    Ferretti G; Fabi A; Carlini P; Papaldo P; Cordiali Fei P; Di Cosimo S; Salesi N; Giannarelli D; Alimonti A; Di Cocco B; D'Agosto G; Bordignon V; Trento E; Cognetti F
    Oncology; 2005; 69(1):35-43. PubMed ID: 16088233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.
    Hirsh V; Major PP; Lipton A; Cook RJ; Langer CJ; Smith MR; Brown JE; Coleman RE
    J Thorac Oncol; 2008 Mar; 3(3):228-36. PubMed ID: 18317064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases.
    Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
    Med Oncol; 2008; 25(3):346-9. PubMed ID: 18204821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients.
    Vincenzi B; Santini D; Dicuonzo G; Battistoni F; Gavasci M; La Cesa A; Grilli C; Virzì V; Gasparro S; Rocci L; Tonini G
    J Interferon Cytokine Res; 2005 Mar; 25(3):144-51. PubMed ID: 15767788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases.
    Zhao YY; Xue C; Hou X; Liao H; Li S; Zhao HY; Huang Y; Chen LK; Xu F; Liu JL; Zhang L
    Eur J Cancer; 2011 Apr; 47(6):848-53. PubMed ID: 21256000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronic acid induces a significant decrease of circulating endothelial cells and circulating endothelial precursor cells in the early prostate cancer neoadjuvant setting.
    Santini D; Zoccoli A; Gregorj C; Di Cerbo M; Iuliani M; Pantano F; Zamarchi R; Sergi F; Flammia G; Buscarini M; Rizzo S; Cicero G; Russo A; Vincenzi B; Avvisati G; Tonini G
    Oncology; 2013; 85(6):342-7. PubMed ID: 24335337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance.
    Zhao X; Xu X; Guo L; Ragaz J; Guo H; Wu J; Shao Z; Zhu J; Guo X; Chen J; Zhu B; Wang Z; Hu X
    Breast Cancer Res Treat; 2010 Dec; 124(3):733-43. PubMed ID: 20882405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
    Xu XJ; Ma DD; Lv F; Wang JY; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Yu W; Li M
    Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?
    Søe K; Plesner T; Jakobsen EH; Hansen CT; Jørgensen HB; Delaissé JM
    J Bone Miner Res; 2013 Aug; 28(8):1738-50. PubMed ID: 23427025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
    Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
    Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid - a multiplicity of anti-cancer action.
    Yuasa T; Kimura S; Ashihara E; Habuchi T; Maekawa T
    Curr Med Chem; 2007; 14(20):2126-35. PubMed ID: 17691952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.
    Holen I; Walker M; Nutter F; Fowles A; Evans CA; Eaton CL; Ottewell PD
    Clin Exp Metastasis; 2016 Mar; 33(3):211-24. PubMed ID: 26585891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
    Saag K; Lindsay R; Kriegman A; Beamer E; Zhou W
    Bone; 2007 May; 40(5):1238-43. PubMed ID: 17347063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer.
    Amir E; Trinkaus M; Simmons CE; Dranitsaris G; Clemons MJ
    J Clin Pathol; 2009 May; 62(5):474-6. PubMed ID: 19398598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.